Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Extension of Employment Agreements of Spiro Rombotis and Paul McBarron

On June 15, 2021, Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the "Company") entered into an Employment Agreement with each of Mr. Spiro Rombotis, President and Chief Executive Officer of the Company and Paul McBarron, Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer of the Company, each of which became effective as of January 1, 2021 (the "Employment Agreements"). On December 28, 2022, the Company entered into an Extension Agreement with each of Mr. Rombotis and Mr. McBarron (the "Extension Agreements"), which extend the term of the Employment Agreements by six months to June 1, 2023. The original terms of the Employment Agreements were scheduled to expire on January 1, 2023. The Extension Agreements will become effective as of January 1, 2023, and all other terms and conditions of the Employment Agreements remain the same.

The foregoing description of the Extension Agreements is a summary and is qualified in its entirety by reference to the terms of the Extension Agreements, which are attached to this Current Report on Form 8-K as Exhibits 10.1 and 10.2 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





(d)     Exhibits.

The following exhibits are being furnished with this Current Report on Form 8-K.





Exhibit No.   Description
   10.1         Extension Agreement between Cyclacel Pharmaceuticals, Inc. and Spiro
              Rombotis, effective as of January 1, 2023.
   10.2         Extension Agreement between Cyclacel Pharmaceuticals, Inc. and Paul
              McBarron, effective as of January 1, 2023.
    104       Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses